US 11110092
Methods of treating hematologic cancers
granted A61KA61K2039/545A61K31/4184
Quick answer
US patent 11110092 (Methods of treating hematologic cancers) held by BioCryst Pharmaceuticals, Inc. expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/545, A61K31/4184, A61K31/519, A61K31/7076